The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ondine Biomedical Inc - Vancouver-based life sciences company - Says it has raised GBP2.9 million via a placing. Says it will issue a further 1.1 million new shares at 9 pence each, representing a 9% premium to the closing price at November 29. Says it will use the proceeds to support its commercialisation in Canada, the UK, Spain and Mexico, and will provide a cash runway until at least the middle of the second quarter in 2024.
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L
InvesterACE, ENET dropped 30% today. OBI only lost 4.75%. lol
9.65-10.29
waiting on exciting new results
Analyst says 60p target
inho dyor
Lol They've just raised millions at 9p. GL
ENET is going to be like yesterday, big drops early morning and 50% up by close. Just buy it now for big profits
So no mention of the current losses cash burn and low cash balances then ?
I expect traders will be selling very soon for a small profit. Newbies left holding the baby here!
I'm all good in here and CMET. I will wait weeks and months not trading for a few quid a day
First sell will walk away with more profits and last to sell will walk away with less. Don't be greedy!
I am watching, hope you make profit though
Just watch and learn 🙉
Nah ENET will be dropping today, you watch
Time to sell up here and move to ENET for bigger money 👍
Funding not an issue and shares getting mopped up by investors
Anyway, I added @9.99, bringing my break even down to 11.96. Now I have a better chance to get out alive, unhurt.
Perhaps not, if it falls back again tomorrow, hahahaha
Polio, do you have another account with the name Ria? Your posts look so similar to his/hers, lol.
Ondine Biomedical Inc - Vancouver-based life sciences company - Raises GBP2.5 million via placing and subscription. Further, in light of the demand for the placing and subscription, increases overall fundraising size from GBP2.5 million cap as commitments already received mean that there are insufficient shares to allocate to the broker option or to employee subscribers.
Expect 15p very soon
imho - dyor
Ticking up on small buys
:)
RBC says overperform with target 60p
10p paid
Currently 9.35-9.95p
It is all up from here
imho - dyor
Close of Bookbuild
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to announce that, further to the announcements made on 30 November 2023 and 1 December 2023, the Bookbuild has now closed.
The Company has successfully raised approximately £2.5 million via binding participations in the Placing and the Subscription. Participants in the Placing will be contacted by Singer Capital Markets Securities Limited ("SCM") or RBC Capital Markets ("RBC", and together with SCM, the "Joint Bookrunners") as soon as practicable to confirm their allocations. A further announcement will be made in due course confirming details of the Placing.
The Company had previously announced a broker option in connection with the Fundraising, which was intended to allow other institutional investors and Relevant Persons to participate. The aggregate Fundraising had been capped at £2.5 million, but in light of the demand for the Placing and Subscription the Company intends to increase the overall Fundraising size, as commitments already received mean that there are insufficient shares to allocate to the Broker Option or to Employee Subscribers.
Further announcements will be made in due course.